UNITED STATES PATENT AND TRADEMARK OFFICE			UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov		
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/328,877	06/09/1999	MARK E. GURNEY	6142.N2-CP	7413	
7590 07/11/2002 PHARMACIA & UPJOHN COMPANY			EXAMINER		
301 HÉNRIETT		TURNER, SHARON L			
KALAMAZOO	, MI 49001		ART UNIT	PAPER NUMBER	
-			1647 / DATE MAILED: 07/11/2002	16	

Please find below and/or attached an Office communication concerning this application or proceeding.

,

•	Application No. Applicant(s) 09/328,877 Gurney et al.						
			Gurney e	rney et al.			
Office Action Summary	Examiner Sharon L. Turner	1	Art Unit 1647				
The MAILING DATE of this communication appears	s on the cover sheet w	ith the corres	spondence add	ress			
<ul> <li>Period for Reply</li> <li>A SHORTENED STATUTORY PERIOD FOR REPLY IS SETHE MAILING DATE OF THIS COMMUNICATION.</li> <li>Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In m mailing date of this communication.</li> <li>If the period for reply specified above is less than thirty (30) days, a reply within the</li> <li>If NO period for reply is specified above, the maximum statutory period will apply an</li> <li>Failure to reply within the set or extended period for reply will, by statute, cause the</li> <li>Any reply received by the Office later than three months after the mailing date of thi earned patent term adjustment. See 37 CFR 1.704(b).</li> </ul>	o event, however, may a reply t statutory minimum of thirty (30) d will expire SIX (6) MONTHS fr application to become ABANDO	be timely filed after days will be cons om the mailing da ONED (35 U.S.C.	<sup>•</sup> SIX (6) MONTHS fro idered timely. te of this communicat § 133).				
Status							
		<u> </u>		<u> </u>			
2a) 🗍 This action is <b>FINAL.</b> 2b) 🕅 This acti							
3) Since this application is in condition for allowance exclosed in accordance with the practice under Ex particle exclosed in accordance with the practice under Ex particle exclosed in accordance with the practice under Ex particle exclosed in accordance with the practice under Ex particle exclosed in accordance with the practice under Ex particle exclosed in accordance with the practice under Ex particle exclosed in accordance with the practice under Ex particle exclosed in accordance with the practice under Ex particle exclosed in accordance with the practice under Ex particle exclosed in accordance with the practice under Ex particle exclosed in accordance with the practice under Ex particle exclosed				erits is			
Disposition of Claims							
4)⊠ Claim(s) <u>42-51</u>			is/are pen	ding in the applica			
4a) Of the above, claim(s)			is/are withdr	awn from considera			
5) 🗌 Claim(s)			is/aı	re allowed.			
6) 🗌 Claim(s)			is/aı	re rejected.			
7) 🗌 Claim(s)		····	is/aı	re objected to.			
8) 🕅 Claims <u>42-51</u>	a	ire subject to	restriction and	l/or election requirem			
Application Papers							
9) $\Box$ The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are a accepted or b objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) $\Box$ The oath or declaration is objected to by the Examine	er.						
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgement is made of a claim for foreign prio	ority under 35 U.S.C. §	119(a)-(d) c	or (f).				
a) All b) Some* c) None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No.							
3. Copies of the certified copies of the priority doc application from the International Bureau *See the attached detailed Office action for a list of the	(PCT Rule 17.2(a)).		National Stag	e			
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).							
a) The translation of the foreign language provisional application has been received.							
15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
1) Notice of References Cited (PTO-892)	4) Interview Summary (P	TO-413) Paper No	o(s).				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)						
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Other:						

Application/Control Number: 09328877/C

Art Unit: 1647

## **Continued Prosecution Application**

1. The request filed on 4-24-02 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 09/328,877 is acceptable and a CPA has been established. An action on the CPA follows.

2. Two Preliminary Amendments filed 4-24-02 have been received by the Office. The first amendment has been entered and has been fully considered. This amendment is directed to the cancellation of claims 1-41 and presentation of new claims 42-51. In a telephone interview with Applicant's representative Edward Rehberg it was determined that the second preliminary amendment directed to claims 3-18 and 44-97 was submitted in error and Applicant's representative requested that the amendment be disregarded as such. Thus, the second amendment has not been entered and the material therein has not been considered further.

## Election/Restriction

3. Restriction to one of the following inventions is required under 35 U.S.C. 121:

I-X. Claims 42-51, drawn respectively to polypeptides of SEQ ID Nos: 3, 4, 5, 6, 7, 8, 9, 21, 25 and 27 classified in class 530, subclass 350.

4. The inventions are distinct, each from the other because of the following reasons:

5. Groups I-X are related as products. The products are different and patentably distinct each from the other as they are comprised of different structural and functional features including different amino acids which are differentially capable of acting as an immunogen, exhibiting specific binding and directing immune responses. Only a search of SEQ ID NO:7 would

## Application/Control Number: 09328877/C

Art Unit: 1647

encompass a search for SEQ ID NO's 3-6 and 8-9 as disclosed in Exhibit A. All other searches are not co-extensive to the other groups. There is no evidence that SEQ ID NO's:21, 25 and 27 would be encompassed by a search for SEQ ID NO:7 as indicated in Exhibit A.

6. Claim 42, Group V, link(s) inventions of claims 43-51, Groups I-IV and VI-X. The restriction requirement between the linked inventions is subject to the nonallowance of the linking claim 42. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

7. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, and their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Application/Control Number: 09328877/C

Page 4

Art Unit: 1647

• •

8. Because these inventions are distinct for the reasons given above and the search required for each of the groups is not required for any other group, restriction for examination purposes as indicated is proper.

9. Applicant is advised that the reply to this requirement to be complete must include an

election of the invention to be examined even though the requirement be traversed (37

CFR 1.143). Applicant should clearly indicate the Group and SEQ ID NO: elected for examination.

10. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Any inquiry of a general nature or relating to the status of this general application should 11. be directed to the Group receptionist whose telephone number is (703) 308-0196.

Papers relating to this application may be submitted to Technology Center 1600, Group 1640 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Should applicant wish to FAX a response, the current FAX number for Group 1600 is (703) 308-4242.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to, Sharon L. Turner, Ph.D. whose telephone number is (703) 308-0056. The examiner can normally be reached on Monday-Thursday from 7:30-6:00 P.M.. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, can be reached at (703) 308-4623.

m

Sharon L. Turner, Ph.D. July 10, 2002